Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 3/20 | 0.38 |
| ▸ | FPR1 | P21462 | 2/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31677885 | 0.85 | KDM4E (0.43) | KDM4ETRPA1MAPTAKR1B1LMNA | |
| SCHEMBL31678822 | 0.84 | KDM4E (0.44) | KDM4ETRPA1MAPTAKR1B1LMNA | |
| SCHEMBL31664578 | 0.83 | KDM4E (0.43) | KDM4ETRPA1MAPTAKR1B1LMNA | |
| SCHEMBL31678803 | 0.83 | MAPT (0.39) | KDM4ETRPA1MAPTAKR1B1KMT2A | |
| SCHEMBL31678840 | 0.79 | RORC (0.39) | KDM4EMAPTAKR1B1KMT2AKDR | |
| SCHEMBL31713851 | 0.78 | PTGDR2 (0.42) | KDM4ETRPA1MAPTAKR1B1LMNA | |
| SCHEMBL31678252 | 0.78 | KDM4E (0.40) | KDM4ETRPA1MAPTAKR1B1KMT2A | |
| SCHEMBL31677892 | 0.77 | KDM4E (0.43) | KDM4ETRPA1MAPTAKR1B1LMNA | |
| SCHEMBL31653799 | 0.77 | ALDH1A1 (0.45) | KDM4ETRPA1MAPTAKR1B1LMNA | |
| SCHEMBL31677815 | 0.76 | KDM4E (0.40) | KDM4ETRPA1MAPTAKR1B1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270218-A1 | IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES AS WRN INHIBITORS | INCYTE CORPORATION (US) | 2025-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270218-A1 | IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES AS WRN INHIBITORS | WRN, RECQL, BLM | KDM4E 3187/4885TRPA1 4243/4885MAPT 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.